Patents by Inventor Wolfgang A. Pieken
Wolfgang A. Pieken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7427678Abstract: This invention discloses a novel method for immobilizing molecules to a support. Specifically, this invention discloses a method of immobilizing derivatized biomolecules, such as oligonucleotides, using cycloaddition reactions, such as the Diels-Alder reaction. Included in this invention are the novel immobilized biomolecules that can be prepared according to the method of this invention.Type: GrantFiled: May 1, 2001Date of Patent: September 23, 2008Assignee: Sigma-Aldrich Co.Inventors: Wolfgang Pieken, Andreas Wolter, David P. Sebesta, Michael Leuck, Hallie A. Latham-Timmons, John Pilon, Gregory M. Husar
-
Patent number: 7098326Abstract: The present invention discloses novel methods for the integrated synthesis and purification of oligonucleotides. The methods employ novel capping reagents carrying two functional groups. The first functional group provides for a smooth and efficient capping process and incorporates the second functional group into contaminant oligonucleotides during solid phase oligonucleotide synthesis. The second functional group functions as a chemical purification handle in the trapping of truncated oligonucleotides (failure sequences) on a solid support. The trapping process creates covalent bonds between the solid support and the truncated oligonucleotides and therefore allows the removal of the truncated sequences from the desired full length oligonucleotide product by filtration. The chemical trapping process employed in this invention is based on cycloaddition reactions, particularly Diels-Alder reactions between the truncated oligonucleotides and the trapping agent.Type: GrantFiled: January 22, 2003Date of Patent: August 29, 2006Assignee: Sigma-Aldrich Co.Inventors: Wolfgang Pieken, Andreas Wolter, Michael Leuck
-
Publication number: 20060036087Abstract: The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2?-position of the ribose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino and disubstituted amino groups, a process for the preparation of modified RNA molecules and the use of modified RNA molecules as therapeutic agents and biocatalysts.Type: ApplicationFiled: September 5, 2003Publication date: February 16, 2006Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David Olsen, David Williams, Olaf Heindenreich
-
Patent number: 6890908Abstract: The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2?-position of the ribose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino and disubstituted amino groups, a process for the preparation of modified RNA molecules and the use of modified RNA molecules as therapeutic agents and biocatalysts.Type: GrantFiled: September 24, 1997Date of Patent: May 10, 2005Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heidenreich
-
Publication number: 20040116685Abstract: This invention discloses an improved method for the sequential solution phase synthesis of oligonucleotides. The method lends itself to automation and is ideally suited for large scale manufacture of oligonucleotides with high efficiency.Type: ApplicationFiled: July 17, 2001Publication date: June 17, 2004Applicant: Proligo LLCInventors: Wolfgang Pieken, Danny McGee, Alecia Settle, Yansheng Zhai, Jianping Huang
-
Patent number: 6737236Abstract: This invention discloses a novel method for conjugating macromolecules to other molecular entities. Specifically, this invention discloses a method for conjugating or derivatizing macromolecules, such as oligonucleotides and proteins, using cycloaddition reactions, such as the Diels-Alder reaction or 1,3-dipolar cycloadditions. Included in the invention are the novel bioconjugated macromolecules that can be prepared according to the method of the invention.Type: GrantFiled: July 8, 1999Date of Patent: May 18, 2004Assignee: Proligo, LLCInventors: Wolfgang Pieken, Ken Hill, Bruce Eaton, Danny McGee, Kurt Vagle, Larry Gold, Andrew Stephens
-
Publication number: 20030215801Abstract: This invention discloses a novel method for immobilizing molecules to a support. Specifically, this invention discloses a method of immobilizing derivatized biomolecules, such as oligonucleotides, using cycloaddition reactions, such as the Diels-Alder reaction. Included in this invention are the novel immobilized biomolecules that can be prepared according to the method of this invention.Type: ApplicationFiled: May 1, 2001Publication date: November 20, 2003Inventors: Wolfgang Pieken, Andreas Wolter, David P. Sebesta, Michael Leuck, Hallie A. Latham-Timmons, John Pilon, Gregory M. Husar
-
Publication number: 20030195351Abstract: The present invention discloses novel methods for the integrated synthesis and purification of oligonucleotides. The methods employ novel capping reagents carrying two functional groups. The first functional group provides for a smooth and efficient capping process and incorporates the second functional group into contaminant oligonucleotides during solid phase oligonucleotide synthesis. The second functional group functions as a chemical purification handle in the trapping of truncated oligonucleotides (failure sequences) on a solid support. The trapping process creates covalent bonds between the solid support and the truncated oligonucleotides and therefore allows the removal of the truncated sequences from the desired full length oligonucleotide product by filtration. The chemical trapping process employed in this invention is based on cycloaddition reactions, particularly Diels-Alder reactions between the truncated oligonucleotides and the trapping agent.Type: ApplicationFiled: January 22, 2003Publication date: October 16, 2003Applicant: PROLIGO, LLCInventors: Wolfgang Pieken, Andreas Wolter, Michael Leuck
-
Publication number: 20020077306Abstract: This invention relates to chemically modified oligo-nucleotide conjugates that contain a complexing agent or complex that is bound by a connecting component to the oligonucleotides. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide radical can bond specifically and with high bonding affinity to target structures and can thus produce a specific therapeutic or diagnostic effect by the bound complexing agent or complex.Type: ApplicationFiled: June 7, 1995Publication date: June 20, 2002Inventors: LUDGER DINKELBORG, CHRISTOPH-STEPHAN HILGER, ULRICH NIEDBALLA, JOHANNES PLATZEK, BERND RADUECHEL, ULRICH SPECK, LARRY GOLD, WOLFGANG PIEKEN
-
Patent number: 6262251Abstract: This invention discloses an improved method for the sequential solution phase synthesis of oligonucleotides. The method lends itself to automation and is ideally suited for large scale manufacture of oligonucleotides with high efficiency.Type: GrantFiled: April 6, 1998Date of Patent: July 17, 2001Assignee: Proligo LLCInventors: Wolfgang Pieken, Danny McGee, Alecia Settle, Yansheng Zhai, Jianping Huang
-
Patent number: 6184364Abstract: Nucleic acid ligands containing modified nucleotides are described as are methods for producing such oligonucleotides. Such ligands enrich the chemical diversity of the candidate mixture for the SELEX process. Specific examples are provided of nucleic acids containing nucleotides modified at the 2′- and 5-position. Specific 2-OH and 2′-NH2 modified RNA ligands to thrombin are described.Type: GrantFiled: September 27, 1999Date of Patent: February 6, 2001Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Wolfgang Pieken, Diane Tasset, Nebojsa Janjic, Larry Gold, Gary P Kirschenheuter
-
Patent number: 6090932Abstract: A method for the preparation of 2'-modified nucleosides is provided. The method comprises a novel intramolecular nucleophilic displacement reaction. Included in the invention are novel 2'-modified pyrimidines and purines prepared according to the method of the invention, novel pyrimidines and purines bearing a 2',3' heterocyclic substituent and oligonucleotides containing said 2'-modified pyrimidines and purines. The 2'-modified nucleosides are useful as anti-viral and anti-neoplastic agents.Type: GrantFiled: October 30, 1996Date of Patent: July 18, 2000Assignee: Proligo LLCInventors: Danny P. McGee, Wolfgang A. Pieken, David P. Sebesta, Yansheng Zhai
-
Patent number: 6001966Abstract: This invention discloses an improved method for the sequential solution phase synthesis of oligonucleotides and peptides. The method lends itself to automation and is ideally suited for large scale manufacture oligonucleotides with high efficiency.Type: GrantFiled: August 6, 1998Date of Patent: December 14, 1999Assignee: Proligo LLCInventors: Wolfgang Pieken, Larry Gold
-
Patent number: 5958691Abstract: Nucleic acid ligands containing modified nucleotides are described as are methods for producing such oligonucleotides. Such ligands enrich the chemical diversity of the candidate mixture for the SELEX process. Specific examples are provided of nucleic acids containing nucleotides modified at the 2'- and 5-position. Specific 2-OH and 2'-NH.sub.2 modified RNA ligands to thrombin are described.Type: GrantFiled: August 25, 1997Date of Patent: September 28, 1999Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Wolfgang Pieken, Diane Tasset, Nebojsa Janjic, Larry Gold, Gary P. Kirschenheuter
-
Patent number: 5874532Abstract: This invention discloses an improved method for the sequential solution phase synthesis of oligonucleotides and peptides. The method lends itself to automation and is ideally suited for large scale manufacture oligonucleotides with high efficiency.Type: GrantFiled: January 8, 1997Date of Patent: February 23, 1999Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Wolfgang Pieken, Larry Gold
-
Patent number: 5817635Abstract: The claimed invention is drawn to RNA molecules with catalytic activity comprising at least one modified nucleoside having a modifier group replacing the hydroxy group at the 2'-position of the ribose sugar where the modifier group is an halo, amino, mono- or disubstituted amino, or an azido group, and methods of use in vivo.Type: GrantFiled: May 4, 1995Date of Patent: October 6, 1998Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heindenreich
-
Patent number: 5698687Abstract: The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2'-position of the fibose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino, and disubstituted andno groups, a process for the preparation of modified KNA molecules and the use of modified KNA molecules as therapeutic agents and biocatalysts.Type: GrantFiled: May 4, 1995Date of Patent: December 16, 1997Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heindenreich
-
Patent number: 5672695Abstract: The claimed invention is drawn to RNA molecules with catalytic activity comprising at least one modified nucleoside having a modifier group replacing the hydroxy group at the 2'-position of the ribose sugar where the modifier group is an halo, amino, mono- or disubstituted amino, or an azido group.Type: GrantFiled: August 9, 1993Date of Patent: September 30, 1997Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Fritz Eckstein, Wolfgang Pieken, Fritz Benseler, David B. Olsen, David M. Williams, Olaf Heidenreich
-
Patent number: 5660985Abstract: Nucleic acid ligands containing modified nucleotides are described as are methods for producing such oligonucleotides. Such ligands enrich the chemical diversity of the candidate mixture for the SELEX process. Specific examples are provided of nucleic acids containing nucleotides modified at the 2'- and 5-position. Specific 2-OH and 2'-NH.sub.2 modified RNA ligands to thrombin are described.Type: GrantFiled: April 27, 1995Date of Patent: August 26, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Wolfgang Pieken, Diane Tasset, Nebojsa Janjic, Larry Gold, Gary P. Kirschenheuter